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INTRODUCTION
Pre-eclampsia (PE) occurs in approximately 2-8% of pregnancies 1 . In developed countries, PE is the primary reason for maternal admission to intensive care units 2 and causes approximately 15% of all pregnancy-related deaths 3 . Additionally, PE is associated with an increased risk of perinatal morbidity and mortality, accounting for approximately 15% of preterm births 4 and 10% of stillbirths 5 .
Due to its complex and only partially known etiology and pathophysiology, there is no single test that can predict PE with sufficient accuracy to be useful clinically 6 . Accordingly, interest in creating screening tests that combine several tests into multiparametric models has increased in recent years. Several of these models, which include maternal characteristics and biophysical and biochemical markers, have a clinically acceptable performance when used in the first trimester 7 -12 , when prophylactic interventions for PE are still effective 13 . Before a prediction model can be considered for use in clinical practice, its predictive performance must be evaluated in datasets that were not used to construct the model, known as external validation 14 . Externally validating the model in a different geographical setting is a good measure of its generalizability and transportability; however, it does not enable differences due to population characteristics or measurement techniques to be differentiated from validity of the model itself 15 . Recently, the performance of a first-trimester prediction model for PE developed in the UK 16 was evaluated in an Australian population 17 , and showed a reduction in the detection rate of early-onset PE from 83% to 41.7% at a fixed 5% false-positive rate (FPR), maintaining similar detection rates for a 10% FPR. The small number of cases in the validation cohort prevent strong conclusions from being drawn.
Problems with the reproducibility of the model due to deficiencies in the design or modeling methods can be detected by external temporal validation 18 , which consists of evaluating prospectively the performance of the model in a subsequent cohort of patients from the same center. The aim of this study was to undertake a temporally external validation of a first-trimester predictive model for PE that was constructed in the routine care setting of an unselected population.
SUBJECTS AND METHODS

Subjects
A model for predicting PE was constructed on a prospective cohort of 5170 women with singleton pregnancies attending for their routine first-trimester ultrasound examination (11 + 0 to 13 + 6 weeks' gestation) at a university hospital in Barcelona between May 2009 and October 2011 12 . A validation cohort was subsequently created from November 2011 to December 2013, including a total of 4621 women also attending for their routine first-trimester ultrasound examination. Of the participants in the validation cohort, a total of 418 (9.0%) were excluded for at least one of the following reasons: missing outcome (n = 252) or predictive (n = 81) data; major fetal defect or chromosomopathy (n = 34); miscarriage or fetal death before 24 weeks' gestation (n = 69); or termination of pregnancy in the absence of medical indication (n = 19). All pregnancies were dated from the first-trimester crown-rump length (CRL) 19 . The local ethics committee approved the study protocol and each patient provided written informed consent.
Predictive variables
Maternal characteristics and medical history were recorded prospectively at the time of the first-trimester ultrasound examination via a patient questionnaire. Characteristics that were recorded included medical and obstetric history, maternal age, ethnicity, smoking status, parity, height and weight.
A nurse measured the participant's blood pressure (BP) automatically with a calibrated M6 Confort device (OMRON Corporation, Kyoto, Japan) in our outpatient clinics, according to standard procedure. BP was measured in one arm (right or left arbitrarily) while the woman was seated and after a 5-min rest. Mean arterial pressure (MAP) was calculated as: diastolic BP + (systolic BP -diastolic BP)/3.
Uterine artery (UtA) Doppler evaluation was performed by transvaginal ultrasound during the first-trimester visit, as described previously 20 . Pulsatility indices (PIs) of both UtAs were measured automatically and the mean UtA-PI was calculated.
Maternal serum pregnancy-associated plasma protein-A (PAPP-A) levels were measured using the DELFIA Xpress analyzer (Perkin-Elmer Life Sciences, Turku, Finland) between 8 and 12 weeks' gestation. Thereafter, PAPP-A levels were converted to multiples of the expected normal median (MoMs), which were corrected for CRL, maternal age, body mass index (BMI), smoking and diabetes status, and ethnicity, according to local references 21 .
Outcome measures
PE was defined as systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg on at least two occasions 4 h apart, developing after 20 weeks' gestation in a previously normotensive woman and proteinuria >300 mg in a 24-h urine specimen 22 . PE superimposed on chronic hypertension was defined as significant proteinuria (as defined above) developing after 20 weeks' gestation in a woman with known chronic hypertension (history of hypertension before conception or presence of hypertension before 20 weeks' gestation). Early-onset PE was defined as PE requiring delivery before 34 weeks' gestation and late-onset PE was defined as PE requiring delivery at or after 34 weeks' gestation. Doctors who made the diagnosis were blinded to the study parameters obtained during the first trimester. Small-for-gestational age was defined as a birth weight < 10 th customized centile and intrauterine growth restriction was defined as a birth weight < 10 th customized centile 23 requiring delivery before 37 weeks' gestation.
Statistical analysis
The Student's t-test and Pearson chi-square test were performed for univariate comparisons of quantitative and qualitative variables, respectively, among groups.
Coefficients for late-onset PE were previously obtained by binomial logistic regression 12 . The formulae for predicting risks that were derived in the construction cohort were subsequently applied to the validation cohort.
In order to account for small-sample bias, the coefficients for early-onset PE were calculated in the construction cohort by logistic regression with penalized likelihood estimation 24 . In order to allow comparison with our previous formulae 12 , the same set of covariates was included in the formulae for prediction of:
• Early-onset PE a-priori risk: BMI, chronic hypertension, renal disease and previous PE, calculated as e y /(1 + e y ), where Y = −5.178 − (0.014 × BMI) + (0.3403 if chronic hypertension) + (0.1927 if renal disease) + (0.8913 if previous PE).
• Early-onset PE a-posteriori risk: log a-priori risk, log MoM mean UtA-PI and log MoM MAP, calculated as e y /(1 + e y ), where Y = −12.297 + (3.4799 × log a-priori risk) + (12.2040 × log MoM mean UtA-PI) + (25.0469 × log MoM MAP).
The expected log mean UtA-PI was calculated according to the model formula: 0.668018 -(0.002772 × CRL) -(0.001536 × height) -(0.001151 × maternal age). The expected log MAP was calculated according to the model formula:
Model performance was evaluated by receiveroperating characteristics (ROC) curve analysis. ROC curves from both cohorts were compared unpaired 25 . A bootstrapping of 2000 replicates was used to determine the 95% CI of the performance parameters. Calibration in the validation cohort was evaluated by plotting the predicted risks against the observed risks, with locally weighted scatterplot smoothing regression, fitting to 50% of the points and an Epanechnikov weight function (kernel).
The statistical software R version 2.15.1 (The R Foundation for Statistical Computing, Vienna, Austria), with the packages penalized 0.9-45 and pROC version 1.7.2, and STATA 13.0 (StataCorp LP, College Station, TX, USA) were used for all statistical analyses and graph construction.
RESULTS
Among the 4203 women included in the study, 169 (4%) developed PE, including 141 (3.4%) cases of late-onset PE and 28 (0.7%) cases of early-onset PE. Table 1 shows the epidemiological and clinical characteristics of the construction and validation cohorts. Significant differences were found between the two groups for ethnicity, smoking status and prevalence of renal and autoimmune diseases and coagulation disorders. In addition, mean BP was significantly higher (albeit irrelevant from a clinical point of view) in the validation cohort (78.8 vs 79.3 mmHg; P < 0.001). Maternal and fetal outcomes in the construction and validation cohorts are summarized in Table 2 . The rates of late-onset PE and small-for-gestational age were significantly higher in the validation cohort.
For prediction of early-onset PE, the model showed an area under the ROC curve of 0.94 (95% CI, 0.88-0.99), which did not differ significantly (P = 0.37) from that obtained in the construction cohort (0.88 (95% CI, 0.78-0.99), Figure 1 ). For prediction of late-onset PE, the model showed an area under the ROC curve of 0.72 (95% CI, 0.66-0.77), which did not differ significantly (P = 0.49) from that obtained in the construction cohort (0.75 (95% CI, 0.67-0.82), Figure 1 ). There was a good correlation between the predicted and observed risks for early-onset PE (Figure 2a) , suggesting good calibration of the model. However, the model showed a trend of overestimating the risk for late-onset PE for predicted risks > 40% (Figure 2b) .
The diagnostic performance of the model for early-and late-onset PE, for FPRs of 5% and 10%, in the validation and construction cohorts is summarized in Table 3 . 
DISCUSSION
Our study shows that a previously published multiparametric model is valid for screening for PE in the first trimester of pregnancy, even when the populations differ slightly in their risk profile.
A systematic review on the quality of first-trimester risk prediction models for PE was published recently 26 . It included 38 multiparametric prediction models, only three of which were found to have used some form of internal validation (leave-one-out cross-validation) 27, 28 , whereas the rest of the series assessed the model performance on the same sample that had been used to develop it (apparent validation). This method of validation is prone to optimistic estimates as model parameters are optimized for data. Internal validation attempts to overcome this limitation by assessing the performance on a random sample from the same underlying population. In addition, three other studies that evaluated the internal validity in reference to systems designed for prediction of PE in the first trimester have been published. One of them evaluated and validated a risk-factor scoring system 29 and the other two evaluated the performance and internal validity of multiparametric models in nulliparous women 30 , including metabolomic biomarkers 31 . Internal validation sets an upper limit to the expected performance in other settings, which is the object of external validation. Regarding external validity, we found conflicting results. Some models performed at a similar level when applied in a different clinical setting from the construction cohort 32, 33 , whereas others underperformed 34, 35 . Oliveira et al. 34 found that, among eight algorithms that were applied in their cohort (USA population), only one achieved a performance comparable to that obtained in construction of the model. Remarkably, this externally validated model was also constructed on a USA population 9 . We agree with the conclusion of Oliveira et al. 34 that the model performance depends on the similarity of the risk profile of the population.
Reassuringly, our study shows that our first-trimester predictive model for early-onset PE retains a good performance when applied in another population. This may be explained partly by the fact that our model was Table 3 Diagnostic performance of model for early-and late-onset pre-eclampsia (PE) in construction and validation cohorts for fixed false-positive rates (FPRs) derived originally from data obtained in routine care in a real-life setting, in which measurements were not obtained by particularly motivated professionals, which may occur in a research setting. In that sense, internal validity (how true are the findings) may conflict with external validity (how generalizable are the results), as highly valid models derived in ideally controlled environments may fail to demonstrate a similarly good performance when replicated externally. We confirmed in our validation cohort a low predictive capacity for late-onset PE, which had already been observed in our construction cohort 12 , as well as in other studies 36 . The development of late-onset PE is thought to be significantly influenced by maternal predisposition, with little or negligible placental component, which explains a much lower prevalence of intrauterine growth restriction that occurs in nearly all cases of early-onset PE. The low degree or absence of placental insufficiency, and the fact that maternal predisposition may occur due to a wide variety of subclinical conditions, makes the prediction of late-onset PE in the first trimester quite challenging. The predictive value of screening for late-onset PE at such early gestational ages has been found consistently to be low in previous studies 7 . This study has several limitations. First, although the sizes of the construction and validation cohorts were appropriate, few cases of early-onset PE occurred (n = 26 and 28, respectively). When the number of events is small, model overfitting can be a problem. An overfitted model tends to demonstrate poor predictive accuracy when applied to new data, but may also undermine external validation. Although we applied frequentist shrinkage methods to alleviate overfitting (penalized methods), we acknowledge that the small number of events in our cohorts may still result in an underpowered validation 37 . Most of the developed and validated models published have the same limitation 26 . Another limitation of our study is that our validation was not fully external. Several external validation techniques can be distinguished, including temporal, spatial and fully external validation, the latter providing the strongest evidence for validity. However, one advantage of the temporal validation that we undertook is that it enables discernment of the validity of the model in itself from differences in the population characteristics or measurement techniques 15 . External validation of our model in a geographically different setting has been planned. We are cautious in assuming a similarly good performance of our model in populations that differ in their ethnic composition or prevalence of cardiovascular risk factors (such as obesity and hypertension) from our South European population in which the model was constructed. Another limitation is that the tested model does not include angiogenic factors as predictors. Evidence is accumulating that the addition of such biochemical factors results in improved diagnostic performance 38, 39 . However, we think that, as these are automated measurements, a negative impact on reproducibility and external validity is unlikely. Finally, data on fetal Doppler were not available for the validation cohort. Therefore, we considered delivery before term as a proxy of the fetal Doppler status. We admit that such a definition may have resulted in a classification bias.
FPR (%) DR (95% CI) (%) PPV (95% CI) (%) NPV (95% CI) (%)
In conclusion, our model has demonstrated validity when applied to a population of women with a slightly higher risk profile. Before widespread use of predictive models for PE in populations that differ from that in which the model was constructed, cautious judgment of the model generalizability is needed.
